GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>IMO, this shows that while the street prices companies on past performance, prospective partners/buyers consider potential.<

The way I would put it is this: The stock market can be notoriously inefficient, but the market for buying and selling drugs and drug companies is generally quite efficient.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”